{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:25:31Z","timestamp":1777418731608,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T00:00:00Z","timestamp":1274745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,7]]},"abstract":"\n Objective:<\/jats:title>\n To determine the role of human papillomavirus (HPV) quadrivalent vaccine in males.<\/jats:p>\n <\/jats:sec>\n \n Data Source:<\/jats:title>\n PubMed (1966\u2013March 2010) was searched using the terms human papillomavirus, human papillomavirus vaccine, quadrivalent, males, cancer, and genital warts. Reference citations were reviewed for relevant information.<\/jats:p>\n <\/jats:sec>\n \n Study Selection and Data Extraction:<\/jats:title>\n All studies including humans and published in English with data describing HPV quadrivalent vaccine administration in males were evaluated.<\/jats:p>\n <\/jats:sec>\n \n Data Synthesis:<\/jats:title>\n The HPV quadrivalent vaccine is currently recommended in females, but its role in males is still being defined. Three clinical trials evaluated the immunogenicity and tolerability of the vaccine in more than 1100 males 9\u201326 years of age. Greater than 99.5% of males seroconverted for HPV 6, 11, 16, and 18 at 1 month post-completion and titers were found to be numerically higher than those in females 16\u201326 years old. One study found that immune response persisted in >92.5% of males at 1 year. The results show high efficacy against detection of new anogenital lesions in males 29 months after receiving the quadrivalent HPV vaccine. In addition, the quadrivalent HPV vaccine appears to be well tolerated, with the most common adverse effects being syncope, fever, local site reactions, dizziness, nausea, and headache.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The HPV quadrivalent vaccine appears to be safe and induces an effective immune response in males. It may also decrease the incidence of anogenital and penile cancer, although current data are limited in number and duration of follow-up. Further analysis of the long-term immunogenicity and effects on HPV-associated complications is needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1p017","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T21:49:44Z","timestamp":1274824184000},"page":"1314-1318","source":"Crossref","is-referenced-by-count":6,"title":["The Prophylactic Role for the Human Papillomavirus Quadrivalent Vaccine in Males"],"prefix":"10.1177","volume":"44","author":[{"given":"Abigail M","family":"Yancey","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie M","family":"Pitlick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia B","family":"Forinash","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,5,25]]},"reference":[{"key":"bibr1-aph.1P017","first-page":"1","author":"Markowitz LE","year":"2007","journal-title":"Morb Mortal Wkly Rep"},{"key":"bibr2-aph.1P017","first-page":"101","volume":"42","author":"Hsuesh PR","year":"2009","journal-title":"J Microbiol Immunol Infect"},{"key":"bibr3-aph.1P017","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.7"},{"key":"bibr4-aph.1P017","unstructured":"American Cancer Society. Human papilloma virus (HPV), cancer, and HPV vaccines. http:\/\/caonline.amcancersoc.org\/cgi\/content\/full\/57\/1\/7 (accessed 2010 Mar 17)."},{"key":"bibr5-aph.1P017","unstructured":"Product information. Gardasil (human papillomavirus quadrivalent 6\/11\/16\/18). Whitehouse Station, NJ: Merck, December 2009."},{"key":"bibr6-aph.1P017","unstructured":"Product information. Cervarix (human papillomavirus bivalent 16\/18). Research Triangle Park, NC: GlaxoSmithKline, December 2009."},{"key":"bibr7-aph.1P017","unstructured":"Centers for Disease Control and Prevention. ACIP provisional recommendations for HPV vaccine. http:\/\/www.cdc.gov\/vaccines\/recs\/provisional\/downloads\/hpv-vac-dec2009-508.pdf (accessed 2010 Mar 5)."},{"key":"bibr8-aph.1P017","unstructured":"Human papillomavirus vaccines: WHO position paper. World Health Organization. Wkly Epidemiol Rec 2009;84:117-32."},{"key":"bibr9-aph.1P017","unstructured":"European Centre for Disease Prevention and Control. European Centre for Disease Prevention and Control issues guidance for the introduction of human papillomavirus (HPV) vaccines in Europe and European union countries. http:\/\/www.eurosurveillance.org\/images\/dynamic\/EE\/VI3N04\/art8022.pdf (accessed 2010 March 17)."},{"key":"bibr10-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.07.023"},{"key":"bibr11-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1159\/000214926"},{"key":"bibr12-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1086\/425271"},{"key":"bibr13-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0461"},{"key":"bibr14-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000253970.29190.5a"},{"key":"bibr15-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181c177fb"},{"key":"bibr16-aph.1P017","unstructured":"GuilanoA, PalefskyJ. Quadrivalent HPV vaccine efficacy against male genital disease and infection (abstract O-01.07). http:\/\/www.hpv2009.org\/Abstractbok_hela%20webb%20low[1].pdf (accessed 2010 Mar 17)."},{"key":"bibr17-aph.1P017","unstructured":"PalefskyJ, GuilanoA. Quadrivalent HPV vaccine efficacy in men having sex with men (abstract O-27.10). http:\/\/www.hpv2009.org\/Abstractbok_hela%20webb%20low[1].pdf (accessed 2010 Mar 17)."},{"key":"bibr18-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1201"},{"key":"bibr19-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3884"},{"key":"bibr20-aph.1P017","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200927020-00004"},{"key":"bibr21-aph.1P017","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604023"},{"key":"bibr22-aph.1P017","doi-asserted-by":"publisher","DOI":"10.3201\/eid1301.060438"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1P017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:46Z","timestamp":1777374466000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1P017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,25]]},"references-count":22,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1345\/aph.1P017"],"URL":"https:\/\/doi.org\/10.1345\/aph.1p017","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,25]]}}}